Verbatim response from Perplexity
The main answer is: it depends on whether you mean “still legally offer compounded GLP-1s” or “still market them anyway.” Based on the results you shared, the telehealth services most clearly identified as still offering compounded GLP-1s are Noom and some smaller operators that received FDA warning letters, while larger brands like Ro and Hims & Hers have largely pivoted toward branded/authorized supply partnerships instead of compounded versions.[5][9][2]
What the results support most clearly:
- Noom is specifically described as still selling compounded GLP-1 versions under the FDA’s personalized-dosing exception, with a separate branded supply arrangement through LillyDirect.[5][9]
- Smaller telehealth brands named in FDA warning letters were still marketing compounded GLP-1s as of the crackdown, including Bliv, Belle, FitRx, BluefitMD, Viv Health/VIV RX, GoodGirlRX, MEDVi, Levity, Ivim, Strut, Peaks, Refills Health, and others listed in the reports.[2][7][8]
- Hims & Hers was specifically singled out by the FDA and later referred for investigation, but the available results suggest it was being pushed away from compounded GLP-1s rather than clearly continuing them in a straightforward way.[3][2]
- Ro and WeightWatchers are described as having pivoted toward authorized branded GLP-1 access and broader obesity-care offerings rather than compounded supply.[5][9]
A practical way to read this in 2026:
- If you want compounded semaglutide/tirzepatide, the safest interpretation is that many telehealth brands no longer offer them openly, and the ones that do are the ones attracting FDA scrutiny.[1][4][6]
- If you want a service that still offers GLP-1 treatment online, the more stable options now appear to be branded/authorized channels like Noom’s LillyDirect-linked offering, Ro, and some other telehealth platforms that have switched away from compounded products.[5][9]
If you want, I can turn this into a brand-by-brand status list of the major telehealth companies and note which ones appear to still have compounded GLP-1 access versus which have moved to branded alternatives.